481 related articles for article (PubMed ID: 27608849)
1. Prognostic value of the Hippo pathway transcriptional coactivators YAP/TAZ and β1-integrin in conventional osteosarcoma.
Bouvier C; Macagno N; Nguyen Q; Loundou A; Jiguet-Jiglaire C; Gentet JC; Jouve JL; Rochwerger A; Mattei JC; Bouvard D; Salas S
Oncotarget; 2016 Oct; 7(40):64702-64710. PubMed ID: 27608849
[TBL] [Abstract][Full Text] [Related]
2. Fibulin-5 promotes airway smooth muscle cell proliferation and migration via modulating Hippo-YAP/TAZ pathway.
Fu J; Zheng M; Zhang X; Zhang Y; Chen Y; Li H; Wang X; Zhang J
Biochem Biophys Res Commun; 2017 Nov; 493(2):985-991. PubMed ID: 28942149
[TBL] [Abstract][Full Text] [Related]
3. The Hippo transducers TAZ/YAP and their target CTGF in male breast cancer.
Di Benedetto A; Mottolese M; Sperati F; Ercolani C; Di Lauro L; Pizzuti L; Vici P; Terrenato I; Sperduti I; Shaaban AM; Sundara-Rajan S; Barba M; Speirs V; De Maria R; Maugeri-Saccà M
Oncotarget; 2016 Jul; 7(28):43188-43198. PubMed ID: 27248471
[TBL] [Abstract][Full Text] [Related]
4. Stearoyl-CoA-desaturase 1 regulates lung cancer stemness via stabilization and nuclear localization of YAP/TAZ.
Noto A; De Vitis C; Pisanu ME; Roscilli G; Ricci G; Catizone A; Sorrentino G; Chianese G; Taglialatela-Scafati O; Trisciuoglio D; Del Bufalo D; Di Martile M; Di Napoli A; Ruco L; Costantini S; Jakopin Z; Budillon A; Melino G; Del Sal G; Ciliberto G; Mancini R
Oncogene; 2017 Aug; 36(32):4573-4584. PubMed ID: 28368399
[TBL] [Abstract][Full Text] [Related]
5. TAZ and YAP are frequently activated oncoproteins in sarcomas.
Fullenkamp CA; Hall SL; Jaber OI; Pakalniskis BL; Savage EC; Savage JM; Ofori-Amanfo GK; Lambertz AM; Ivins SD; Stipp CS; Miller BJ; Milhem MM; Tanas MR
Oncotarget; 2016 May; 7(21):30094-108. PubMed ID: 27129148
[TBL] [Abstract][Full Text] [Related]
6. YAP/TAZ for cancer therapy: opportunities and challenges (review).
Guo L; Teng L
Int J Oncol; 2015 Apr; 46(4):1444-52. PubMed ID: 25652178
[TBL] [Abstract][Full Text] [Related]
7. Type I collagen deposition via osteoinduction ameliorates YAP/TAZ activity in 3D floating culture clumps of mesenchymal stem cell/extracellular matrix complexes.
Komatsu N; Kajiya M; Motoike S; Takewaki M; Horikoshi S; Iwata T; Ouhara K; Takeda K; Matsuda S; Fujita T; Kurihara H
Stem Cell Res Ther; 2018 Dec; 9(1):342. PubMed ID: 30526677
[TBL] [Abstract][Full Text] [Related]
8. Non-hippo kinases: indispensable roles in YAP/TAZ signaling and implications in cancer therapy.
Zhu J; Wu T; Lin Q
Mol Biol Rep; 2023 May; 50(5):4565-4578. PubMed ID: 36877351
[TBL] [Abstract][Full Text] [Related]
9. Transcriptional co-repressor function of the hippo pathway transducers YAP and TAZ.
Kim M; Kim T; Johnson RL; Lim DS
Cell Rep; 2015 Apr; 11(2):270-82. PubMed ID: 25843714
[TBL] [Abstract][Full Text] [Related]
10. The Hippo Pathway in Prostate Cancer.
Salem O; Hansen CG
Cells; 2019 Apr; 8(4):. PubMed ID: 31018586
[TBL] [Abstract][Full Text] [Related]
11. Arhgef7 promotes activation of the Hippo pathway core kinase Lats.
Heidary Arash E; Song KM; Song S; Shiban A; Attisano L
EMBO J; 2014 Dec; 33(24):2997-3011. PubMed ID: 25425573
[TBL] [Abstract][Full Text] [Related]
12. The Hippo pathway effectors YAP and TAZ promote cell growth by modulating amino acid signaling to mTORC1.
Hansen CG; Ng YL; Lam WL; Plouffe SW; Guan KL
Cell Res; 2015 Dec; 25(12):1299-313. PubMed ID: 26611634
[TBL] [Abstract][Full Text] [Related]
13. Reciprocal regulation of YAP/TAZ by the Hippo pathway and the Small GTPase pathway.
Jang JW; Kim MK; Bae SC
Small GTPases; 2020 Jul; 11(4):280-288. PubMed ID: 29457552
[TBL] [Abstract][Full Text] [Related]
14. Integrin α2β1 inhibits MST1 kinase phosphorylation and activates Yes-associated protein oncogenic signaling in hepatocellular carcinoma.
Wong KF; Liu AM; Hong W; Xu Z; Luk JM
Oncotarget; 2016 Nov; 7(47):77683-77695. PubMed ID: 27765911
[TBL] [Abstract][Full Text] [Related]
15. YAP and TAZ differentially regulate postnatal cortical progenitor proliferation and astrocyte differentiation.
Chen J; Tsai YH; Linden AK; Kessler JA; Peng CY
J Cell Sci; 2024 May; 137(10):. PubMed ID: 38813860
[TBL] [Abstract][Full Text] [Related]
16. Role of YAP/TAZ transcriptional regulators in resistance to anti-cancer therapies.
Kim MH; Kim J
Cell Mol Life Sci; 2017 Apr; 74(8):1457-1474. PubMed ID: 27826640
[TBL] [Abstract][Full Text] [Related]
17. The Hippo pathway in normal development and cancer.
Maugeri-Saccà M; De Maria R
Pharmacol Ther; 2018 Jun; 186():60-72. PubMed ID: 29305295
[TBL] [Abstract][Full Text] [Related]
18. Metabolic control of YAP and TAZ by the mevalonate pathway.
Sorrentino G; Ruggeri N; Specchia V; Cordenonsi M; Mano M; Dupont S; Manfrin A; Ingallina E; Sommaggio R; Piazza S; Rosato A; Piccolo S; Del Sal G
Nat Cell Biol; 2014 Apr; 16(4):357-66. PubMed ID: 24658687
[TBL] [Abstract][Full Text] [Related]
19. Tissue inhibitor of metalloproteinase-1 promotes cell proliferation through YAP/TAZ activation in cancer.
Ando T; Charindra D; Shrestha M; Umehara H; Ogawa I; Miyauchi M; Takata T
Oncogene; 2018 Jan; 37(2):263-270. PubMed ID: 28925394
[TBL] [Abstract][Full Text] [Related]
20. Integrin signalling regulates YAP and TAZ to control skin homeostasis.
Elbediwy A; Vincent-Mistiaen ZI; Spencer-Dene B; Stone RK; Boeing S; Wculek SK; Cordero J; Tan EH; Ridgway R; Brunton VG; Sahai E; Gerhardt H; Behrens A; Malanchi I; Sansom OJ; Thompson BJ
Development; 2016 May; 143(10):1674-87. PubMed ID: 26989177
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
